Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy and Safety of a Novel Copper Modulating Agent (WTX-101) for Wilson Disease: Results of a Phase 2, Multi-Center, Open Label Study
Movement Disorders
P2 - (-)
026
Authors/Disclosures
Danny Bega, MD (Northwestern University)
PRESENTER 		Dr. Bega has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus Pharmaceuticals. Dr. Bega has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SOM. Dr. Bega has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva Pharmaceuticals. Dr. Bega has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine Biosciences.
No disclosure on file
No disclosure on file
Jeff M. Bronstein, MD, PhD (UCLA) Dr. Bronstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ultragenyx. The institution of Dr. Bronstein has received research support from NIH. The institution of Dr. Bronstein has received research support from Levine Foundation.
Anna Czlonkowska, MD (Institute of Psychiatry and Neurology) Dr. Czlonkowska has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Alexion.
No disclosure on file
David J. Nicholl, PhD, FRCP Dr. Nicholl has nothing to disclose.
No disclosure on file
No disclosure on file